Commentary on oncolytic viruses: past, present, and future
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, onc...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Publishing Group
2023-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Acceso en liña: | https://jitc.bmj.com/content/11/12/e007905.full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|